Non-squamous Non-small Cell Lung Cancer

Oncology
17
Pipeline Programs
7
Companies
22
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
8
0
6
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
450%
Monoclonal Antibody
338%
ADC
113%
+ 7 programs with unclassified modality

On Market (3)

Approved therapies currently available

Roche
AVASTINApproved
bevacizumab
Roche
Vascular Endothelial Growth Factor Inhibitor [EPC]intravenous2004
U
PACLITAXELApproved
paclitaxel
Unknown Company
Microtubule Inhibitor [EPC]intravenous2024
Roche
TECENTRIQApproved
atezolizumab
Roche
Programmed Death Receptor-1 Blocking Antibody [EPC]injection2016

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Roche
RocheSTAVANGER NORWAY, Norway
8 programs
4
3
1
AtezolizumabPhase 3Monoclonal Antibody1 trial
BevacizumabPhase 3Monoclonal Antibody1 trial
erlotinibPhase 3Small Molecule1 trial
ErlotinibPhase 2Small Molecule1 trial
ErlotinibPhase 2Small Molecule1 trial
+3 more programs
Active Trials
NCT02596958Completed996Est. Oct 2013
NCT00518011Completed17Est. Feb 2009
NCT02774278Completed264Est. Jun 2009
+5 more trials
Genentech
GenentechCA - Oceanside
2 programs
1
1
ErlotinibPhase 3Small Molecule1 trial
ixabepilonePhase 2
Active Trials
NCT01456325Completed494Est. Jan 2016
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
PaclitaxelPhase 32 trials
Active Trials
NCT03595059Completed168Est. Sep 2025
NCT02264990Completed595Est. Feb 2020
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QL1101Phase 31 trial
Active Trials
NCT03169335CompletedEst. Jul 2018
Sanofi
SanofiPARIS, France
1 program
1
Tusamitamab ravtansinePhase 2ADC1 trial
Active Trials
NCT05245071Terminated22Est. Nov 2024
Bristol Myers Squibb
1 program
1
ixabepilonePhase 25 trials
Active Trials
NCT01454479Unknown24Est. Apr 2014
NCT01057212Terminated6Est. Dec 2013
NCT01075100Completed103Est. Jun 2013
+2 more trials
Providence Therapeutics
1 program
1
ixabepilonePhase 2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Qilu PharmaceuticalQL1101
AbbViePaclitaxel
RocheAtezolizumab
Rocheerlotinib
GenentechErlotinib
RocheBevacizumab
SanofiTusamitamab ravtansine
RocheRO5083945
Bristol Myers Squibbixabepilone
RocheRO4929097
Bristol Myers Squibbixabepilone
Bristol Myers Squibbixabepilone
Bristol Myers Squibbixabepilone
Bristol Myers Squibbixabepilone
Bristol Myers Squibbixabepilone

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 4,679 patients across 22 trials

NCT03169335Qilu PharmaceuticalQL1101

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

Start: Mar 2017Est. completion: Jul 2018
Phase 3Completed
NCT02264990AbbViePaclitaxel

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

Start: Sep 2014Est. completion: Feb 2020595 patients
Phase 3Completed
NCT02008227RocheAtezolizumab

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Start: Mar 2014Est. completion: Jan 20191,225 patients
Phase 3Completed
NCT01887886Rocheerlotinib

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Start: Dec 2013Est. completion: Feb 201510 patients
Phase 3Completed
NCT01456325GenentechErlotinib

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Start: Jan 2012Est. completion: Jan 2016494 patients
Phase 3Completed
NCT01351415RocheBevacizumab

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Start: Jun 2011Est. completion: Jun 2016485 patients
Phase 3Completed
NCT05245071SanofiTusamitamab ravtansine

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA

Start: Jun 2022Est. completion: Nov 202422 patients
Phase 2Terminated
NCT01185847RocheRO5083945

A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Start: Nov 2010Est. completion: Sep 201290 patients
Phase 2Completed
NCT01057212Bristol Myers Squibbixabepilone

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Start: Feb 2010Est. completion: Dec 20136 patients
Phase 2Terminated
NCT01070927RocheRO4929097

An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer

Start: Jan 2010Est. completion: Aug 20107 patients
Phase 2Completed
NCT01075100Bristol Myers Squibbixabepilone

Ixabepilone + Carboplatin Metastatic Breast Cancer

Start: Jan 2010Est. completion: Jun 2013103 patients
Phase 2Completed
NCT00821886Bristol Myers Squibbixabepilone

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

Start: Feb 2009Est. completion: Oct 201460 patients
Phase 2Completed
NCT00741988Bristol Myers Squibbixabepilone

Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

Start: Sep 2008Est. completion: Sep 201282 patients
Phase 2Completed
NCT00672009Bristol Myers Squibbixabepilone

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer

Start: Apr 2008Est. completion: Aug 201211 patients
Phase 2Terminated
NCT00627978Bristol Myers Squibbixabepilone

Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons

Start: Nov 2007Est. completion: Jan 201115 patients
Phase 2Completed
NCT00518011RocheErlotinib

A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.

Start: Aug 2007Est. completion: Feb 200917 patients
Phase 2Completed
NCT02774278RocheErlotinib

A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)

Start: Jul 2005Est. completion: Jun 2009264 patients
Phase 2Completed
NCT00017043Bristol Myers Squibbixabepilone

BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With Chemotherapy

Start: Feb 2001Est. completion: Jan 2003
Phase 2Completed
NCT03595059AbbViePaclitaxel

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

Start: Jul 2018Est. completion: Sep 2025168 patients
Phase 1Completed
NCT01454479Bristol Myers Squibbixabepilone

A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Start: Mar 2011Est. completion: Apr 201424 patients
Phase 1Unknown
NCT00804310Bristol Myers Squibbixabepilone

Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors

Start: Aug 2009Est. completion: Sep 20115 patients
Phase 1Terminated
NCT02596958RocheBevacizumab

Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants

Start: Sep 2007Est. completion: Oct 2013996 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3m ago

Office Administrator

SystImmune
3m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
17m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
17m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)